An approved pilot study is underway that explores the impact of wearing two Fos Biomedical devices in combination with orally administered Copper Glycinate (2mg BID). It is believed that the combination of this particular form of light therapy in conjunction with copper ions will produce an antiviral effect. A sample of convenience of up to 40 subjects, both men and women aged 18-70 will be selected to participate.